CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 6, 2006--Gloucester Pharmaceuticals, Inc.: Gloucester Pharmaceuticals, Inc., a privately held cancer therapeutics development company, announced today that interim results from the Company's pivotal trial of depsipeptide in cutaneous T-cell lymphoma (CTCL) were reported at the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place this week in Atlanta, GA.
